28. Systemic amyloidosis Clinical trials / Disease details

Clinical trials : 267 /  Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05184088
(ClinicalTrials.gov)		January 13, 20236/1/2022Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisAn Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL AmyloidosisCardiac Amyloidosis;AL Amyloidosis;ATTR AmyloidosisDrug: [18F]florbetabenLife Molecular Imaging GmbHpharmtrace klinische Entwicklung GmbHRecruiting18 YearsN/AAll200Phase 3Spain
2NCT04392960
(ClinicalTrials.gov)		July 22, 202027/2/2020Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL AmyloidosisMolecular, Magnetic Resonance, and Echocardiographic Imaging Combined With Biomarkers of Cardiac and Clonal Disease to Predict Survival and Assess Response to Therapy in Cardiac AL AmyloidosisAL AmyloidosisDrug: [18F]FlorbetabenIRCCS Policlinico S. MatteoNULLRecruiting18 YearsN/AAll69N/AItaly